Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Expanded Access
Expanded Access
Temporarily not available
- Available: Expanded access is currently available for this investigational treatment, and patients who are not participants in the clinical study may be able to gain access to the drug, biologic, or medical device being studied.
- No longer available: Expanded access was available for this intervention previously but is not currently available and will not be available in the future.
- Temporarily not available: Expanded access is not currently available for this intervention but is expected to be available in the future.
- Approved for marketing: The intervention has been approved by the U.S. Food and Drug Administration for use by the public.
Contacts and Locations
Study Contact
Study Contact
- Name: Study Contact
- Phone Number: 844-434-4210
- Email: Participate-In-This-Study1@its.jnj.com
Study Locations
-
-
-
Buenos Aires, Argentina, C1199ABB
- Active, not recruiting
- Hospital Italiano de Buenos Aires
-
Buenos Aires, Argentina, C1428AQK
- Recruiting
- Instituto Fleni
-
Buenos Aires, Argentina, C1428
- Completed
- Hospital Gral Agudos Ignacio Pirovano
-
Rosario, Argentina, 2900
- Recruiting
- INECO Neurociencias Orono
-
-
-
-
-
Melbourne, Australia, 3004
- Completed
- The Alfred Hospital
-
Parkwood, Australia, 4215
- Completed
- Gold Coast University Hospital
-
-
-
-
-
Ottawa, Canada, K1N 6N5
- Recruiting
- The Ottawa Hospital Ottawa NeuroMuscular Centre
-
-
-
-
-
Beijing, China, 100191
- Completed
- Peking University Third Hospital
-
Beijing, China, 100034
- Completed
- Peking University First Hospital
-
Beijing, China, 100053
- Active, not recruiting
- Xuanwu Hospital ,Capital Medical University
-
Beijing, China, 100070
- Active, not recruiting
- Beijing Tiantan Hospital, Capital Medical University
-
Changchun, China, 130021
- Active, not recruiting
- The First Hospital of Jilin University
-
Changsha, China, 410008
- Completed
- Xiangya Hospital Central South University
-
Changsha, China, 410008
- Active, not recruiting
- The Third Xiangya Hospital of Central Sourth University
-
Chengdu, China, 610072
- Completed
- Sichuan Provincial Peoples Hospital
-
Chifeng, China, 024000
- Completed
- Chifeng Municipal Hospital
-
Fuzhou, China, 350001
- Active, not recruiting
- Fujian Medical University Union Hospital
-
Guangzhou, China, 510080
- Active, not recruiting
- The First Affiliated Hospital Sun Yat sen University
-
Jinan, China, 250012
- Active, not recruiting
- Qilu Hospital of Shandong University
-
Jinan, China, 250014
- Completed
- Qianfoshan hospital of Shandong Province
-
Nanchang, China, 330006
- Active, not recruiting
- The First Affiliated Hospital of NanChang University
-
Shanghai, China, 200336
- Completed
- Tong Ren Hospital Shanghai Jiao Tong University school of medicine
-
Shanghai, China, 200040
- Active, not recruiting
- Huashan Hospital Fudan University
-
Wuhan, China, 430023
- Completed
- Renmin Hospital of Wuhan University
-
Xi'an, China, 710032
- Completed
- Tangdu hospital the Fourth Military Medical
-
Xi'an, China, 710075
- Active, not recruiting
- Xi 'an GaoXin Hospital
-
-
-
-
-
Floridablanca, Colombia, 681004
- Completed
- Fundación Cardiovascular de Colombia - Instituto del Corazón Floridablanca
-
Medellín, Colombia, 50021
- Active, not recruiting
- Instituto Neurológico de Colombia
-
-
-
-
-
Hradec Králové, Czechia, 500 05
- Active, not recruiting
- Fakultni nemocnice Hradec Kralove
-
Ostrava, Czechia, 708 52
- Completed
- Fakultni Nemocnice Ostrava
-
Pardubice, Czechia, 53203
- Completed
- Pardubicka krajska nemocnice a s
-
-
-
-
-
Bordeaux, France, 33000
- Completed
- CHU Bordeaux
-
Bron, France, 69699
- Completed
- Hospices Civils de Lyon HCL
-
Le Kremlin-Bicêtre, France, 94270
- Active, not recruiting
- Hopital de Bicetre
-
Marseille, France, 13385
- Active, not recruiting
- Hopital de la Timone
-
Nice, France, 06000
- Active, not recruiting
- Hopital PASTEUR
-
Nîmes, France, 30029
- Active, not recruiting
- CHU Nimes Hopital Caremeau
-
Paris, France, 75013
- Completed
- Hopital de la Pitie Salpetriere
-
Paris, France, 75019
- Completed
- Fondation Adolphe de Rothschild Hospital
-
Strasbourg, France, 67200
- Active, not recruiting
- CHRU Strasbourg
-
-
-
-
-
Berlin, Germany, 13347
- Active, not recruiting
- Judisches Krankenhaus Berlin
-
Bochum, Germany, 44791
- Completed
- St. Josef-Hospital, Ruhr-Universität Bochum
-
Halle, Germany, 6120
- Active, not recruiting
- Städtisches Krankenhaus Martha-Maria Halle-Dölau gGmbH
-
Hanover, Germany, 30625
- Active, not recruiting
- Medizinische Hochschule Hannover
-
Leipzig, Germany, 4103
- Completed
- Universitaetsklinikum Leipzig
-
Potsdam, Germany, 14471
- Completed
- St Josefs Krankenhaus Potsdam Sanssouci
-
-
-
-
-
Athens, Greece, 12462
- Recruiting
- Attikon General Hospital of Athens
-
Athens, Greece, 11527
- Completed
- Papageorgiou General Hospital Of Thessaloniki
-
Pátrai, Greece, 26504
- Completed
- Patras University Hospital
-
Thessaloniki, Greece, 54636
- Recruiting
- Ahepa Hospital Aristotle University of Thessaloniki
-
-
-
-
-
Catania, Italy, 95123
- Completed
- Azienda Ospedaliero-Universitaria Policlinico di Catania
-
Genova, Italy, 16132
- Completed
- Azienda Ospedaliera Universitaria San Martino di Genova
-
Milan, Italy, 20144
- Completed
- Casa di Cura del Policlinico
-
Milan, Italy, 20133
- Completed
- Istituto Neurologico Carlo Besta
-
Naples, Italy, 80131
- Active, not recruiting
- Azienda Ospedaliera di Rilievo Nazionale A Cardarelli
-
Orbassano, Italy, 10043
- Completed
- Aou San Luigi Gonzaga
-
Pavia, Italy, 27100
- Completed
- Fondazione Istituto Neurologico Casimiro Mondino
-
Roma, Italy, 00168
- Completed
- Fondazione Policlinico Universitario A Gemelli IRCCS
-
Rozzano, Italy, 20086
- Completed
- IRCCS Istituto Clinico Humanitas
-
-
-
-
-
Asahikawa, Japan, 070-0901
- Active, not recruiting
- National Hospital Organization Asahikawa Medical Center
-
Bunkyō City, Japan, 113 8519
- Active, not recruiting
- Institute of Science Tokyo Hospital
-
Chiba, Japan, 260-8677
- Completed
- Chiba University Hospital
-
Hamamatsu, Japan, 430-8558
- Active, not recruiting
- Seirei Hamamatsu General Hospital
-
Isehara, Japan, 259-1193
- Active, not recruiting
- Tokai University Hospital
-
Kobe, Japan, 650 0047
- Completed
- Kobe City Medical Center General Hospital
-
Kodaira-shi, Japan, 187-8551
- Active, not recruiting
- National Center of Neurology and Psychiatry
-
Koshigaya, Japan, 343-8555
- Active, not recruiting
- Saitama Medical Center
-
Kumamoto, Japan, 860-8556
- Completed
- Kumamoto University Hospital
-
Nagoya, Japan, 466-8560
- Active, not recruiting
- Nagoya University Hospital
-
Nagoya, Japan, 455-8530
- Active, not recruiting
- Chubu Rosai Hospital
-
Osaka Sayama Shi, Japan, 589 8511
- Completed
- Kindai University Hospital
-
Sendai, Japan, 983-8520
- Active, not recruiting
- National Hospital Organization Sendai Medical Center
-
Shimotsuga Gun, Japan, 321 0293
- Completed
- Dokkyo Medical University Hospital
-
Shinjuku-ku, Japan, 162-8666
- Completed
- Tokyo Women's Medical University Hospital
-
Tenri, Japan, 632-0015
- Completed
- Tenri Hospital
-
Toon-shi, Japan, 791-0295
- Completed
- Ehime University Hospital
-
Toyama, Japan, 930-0194
- Completed
- Toyama University Hospital
-
Ube, Japan, 755-8505
- Completed
- Yamaguchi University Hospital
-
-
-
-
-
Monterrey, Mexico, 64710
- Completed
- i Can Oncology Center
-
Tlalnepantla, Mexico, 54055
- Recruiting
- Clinical Research Institute S.C.
-
-
-
-
-
Chorzów, Poland, 41 500
- Completed
- Centrum Medyczne
-
Krakow, Poland, 30 539
- Completed
- Specjalistyczne Gabinety Lekarskie
-
Lublin, Poland, 20 093
- Completed
- Prywatny Gabinet Lekarski
-
Poznan, Poland, 61 731
- Active, not recruiting
- Clinical Research Center sp z o o MEDIC R s k
-
-
-
-
-
Almada, Portugal, 2805-267
- Active, not recruiting
- Hospital Garcia de Orta
-
Braga, Portugal, 4710-243
- Completed
- Hospital de Braga
-
Porto, Portugal, 4200 319
- Active, not recruiting
- Centro Hospitalar de Sao Joao Epe
-
-
-
-
-
Seoul, South Korea, 05030
- Completed
- Konkuk University Medical Center
-
Seoul, South Korea, 02447
- Completed
- Kyunghee University Medical Center
-
Seoul, South Korea, 135-710
- Completed
- Samsung Medical Center
-
-
-
-
-
Alicante, Spain, 03010
- Active, not recruiting
- Hosp. Gral. Univ. de Alicante
-
Barcelona, Spain, 8035
- Completed
- Hosp Univ Vall D Hebron
-
Bilbao, Spain, 48013
- Active, not recruiting
- Hosp. Univ. de Basurto
-
Donostia / San Sebastian, Spain, 20014
- Completed
- Hosp. Univ. Donostia
-
Madrid, Spain, 28040
- Completed
- Hosp. Clinico San Carlos
-
Seville, Spain, 41009
- Active, not recruiting
- Hosp. Virgen Macarena
-
-
-
-
-
Kaohsiung City, Taiwan, 88301
- Completed
- Kaohsiung Chang Gung Memorial Hospital
-
Taipei, Taiwan, 100
- Active, not recruiting
- National Taiwan University Hospital
-
Taipei, Taiwan, 111
- Active, not recruiting
- Shin Kong Wu Ho Su Memorial Hospital
-
-
-
-
-
Birmingham, United Kingdom, B15 2TH
- Completed
- University Hospitals Birmingham NHS Foundation Trust
-
Devon, United Kingdom, EX2 5DW
- Completed
- Royal Devon & Exeter Hospital
-
Glasgow, United Kingdom, G514TF
- Active, not recruiting
- NHS Greater Glasgow and Clyde
-
London, United Kingdom, NW3 2QG
- Completed
- Royal Free Hospital
-
Sheffield, United Kingdom, S10 2 JF
- Active, not recruiting
- Sheffield Teaching Hospitals NHS Foundation Trust
-
-
-
-
Colorado
-
Centennial, Colorado, United States, 80112
- Active, not recruiting
- IMMUNOe Health and Research Centers
-
-
Florida
-
Coral Springs, Florida, United States, 33067
- Completed
- Healthcare Innovations Institute Inc
-
Maitland, Florida, United States, 32751
- Completed
- Neurology Associates PA
-
Miami, Florida, United States, 33136
- Active, not recruiting
- ALS Center at the University of Miami
-
-
Georgia
-
Augusta, Georgia, United States, 30912
- Completed
- Augusta University
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- Completed
- University of Kansas Medical Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Completed
- Johns Hopkins Hospital
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Completed
- Boston Clinical Trials
-
-
Michigan
-
Royal Oak, Michigan, United States, 48073
- Completed
- Beaumont Hospital Royal Oak
-
-
Missouri
-
Kansas City, Missouri, United States, 64128
- Completed
- Kansas City Veterans Affairs Medical Center
-
-
New York
-
New York, New York, United States, 10032
- Completed
- The Neurological Institute of New York
-
Patchogue, New York, United States, 11772
- Completed
- South Shore Neurologic Associates - Patchogue
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Completed
- The Neurological Institute, PA
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Active, not recruiting
- Cleveland Clinic Main Campus
-
-
Texas
-
Austin, Texas, United States, 78756
- Completed
- Austin Neuromuscular Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53215
- Active, not recruiting
- Advocate Health - Aurora St. Luke's Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults greater than or equal to (>=) 18 years of age at the time of consent and as applicable, must also meet the legal age of consent in the jurisdiction in which the study is taking place
- Diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) according to criteria of the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) 2021, progressing or relapsing forms. CIDP diagnosis to be adjudicated by independent committee during screening period
- Inflammatory Neuropathy Cause and Treatment (INCAT) disability score between 2 and 9 at the Run-In Baseline visit for participants entering Run-In, or Stage A Baseline visit for participants directly entering Stage A. Participants with an INCAT score of 2 at trial entry must have this score exclusively from the leg disability score
- Fulfilling any of the following treatment conditions: a) Currently treated with oral corticosteroids (CS) less than or equal to (<=) 20 milligrams (mg)/day; or b) Currently treated with pulsed CS, and/or intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg) and the participant is willing to discontinue no later than the run-in baseline visit; or c) Currently treated with oral CS greater than (>) 20 mg/day and the participant is willing to taper to <=20 mg/day during the run-in period; or d) Without previous treatment (treatment naive); or treatment with CS and/or IVIg or SCIg discontinued at least 3 months prior to screening (untreated)
- Active disease as determined by CIDP Disease Activity Status (CDAS) score >= 3
- Other protocol-defined inclusion criteria will apply
Exclusion Criteria:
- Has a history of severe and/or uncontrolled hepatic (example, viral/alcoholic/autoimmune hepatitis/cirrhosis and/or metabolic liver disease), gastrointestinal, renal, pulmonary, cardiovascular, psychiatric, neurological or musculoskeletal disorder, hypertension and/or any other medical or uncontrolled autoimmune disorder(s) (example, diabetes mellitus) or clinically significant abnormalities in screening laboratory that, might interfere with the participants full participation in the study, or might jeopardize the safety of the participant or the validity of the study results
- Pure sensory CIDP or chronic immune sensory polyradiculopathy (CISP) (EAN/PNS definition)
- Any other disease that could better explain the participant's signs and symptoms, such as significant persisting neurological deficits from stroke or central nervous system (CNS) trauma or peripheral neuropathy from another cause such as connective tissue disease or systemic lupus erythematosus
- Polyneuropathy of other causes, including the following: Multifocal motor neuropathy (MMN); Monoclonal gammopathy of uncertain significance with antimyelin associated glycoprotein (anti-MAG) immunoglobulin M (IgM) antibodies; Hereditary motor neuropathy; Hereditary neuropathy with liability to pressure palsies (HNPP); Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change syndromes; Lumbosacral radiculoplexus neuropathy; Polyneuropathy most likely due to diabetes mellitus; Polyneuropathy most likely due to systemic illnesses; Drug- or toxin-induced polyneuropathy Note: A concomitant polyneuropathy of other causes (example, a mild, stable diabetic polyneuropathy) is not necessarily exclusionary if chronic inflammatory demyelinating polyneuropathy (CIDP) is confirmed as the main diagnosis, as determined by the investigator and confirmed by the adjudication committee
- Has known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients
- Other protocol-defined exclusion criteria will apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Nipocalimab
Participants in Stage A (Open-label) will receive a loading dose of nipocalimab (Dose 1) intravenous (IV) infusion on Day 1, followed by nipocalimab (Dose 2) IV infusion once every 2 weeks (q2w) from Week 2 to Week 12. Participants who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive nipocalimab (Dose 2) IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first. |
Nipocalimab will be administered intravenously.
Other Names:
|
|
Placebo Comparator: Placebo
Participants receiving nipocalimab in Stage A and who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive placebo IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first. |
Placebo will be administered intravenously. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Stage B: Time to First Occurrence of a Relapse Event
Time Frame: Up to 52 weeks
|
Stage B time to first occurrence of a relapse event will be reported. |
Up to 52 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Stage A: Time to Initial Confirmed Evidence of Clinical Improvement (ECI)
Time Frame: 12 weeks
|
Time to initial confirmed ECI will be reported. |
12 weeks
|
|
Stage A: Percentage of Responders as Determined by ECI
Time Frame: 12 weeks
|
Stage A percentage of responders as determined by ECI will be reported. |
12 weeks
|
|
Stage A: Change from Baseline Over Time in Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale Score
Time Frame: Baseline to 12 weeks
|
Change from Stage A baseline over time in adjusted INCAT disability scale score will be reported. The INCAT disability scale is a clinician-rated assessment that measures activity limitation and degree of functional disability. The INCAT scale is an ordinal scale scored from 0 to 10, with higher scores indicating more disability. |
Baseline to 12 weeks
|
|
Stage A: Change from Stage A Baseline Over Time in Medical Research Council (MRC) Muscle Grading Scale Sum Score
Time Frame: Baseline to 12 weeks
|
Change from Stage A baseline over time in MRC muscle grading scale sum score will be reported. The MRC muscle grading scale is a clinician-rated outcome that provides a strength rating (on a scale from 0 [no visible contraction] to 5 [normal]) in 6 muscles collected bilaterally: deltoid, biceps, wrist extensors, iliopsoas, quadriceps, tibialis anterior. Lower scores indicate greater impairment. |
Baseline to 12 weeks
|
|
Stage A: Change from Baseline Over Time in Inflammatory Rasch-Built Overall Disability Scale (I-RODS) Centile Score
Time Frame: Baseline to 12 weeks
|
Change from Stage A baseline over time in I-RODS centile score will be reported. The I-RODS comprises of 24 items representing common daily activities that address upper and lower limb disability and range in difficulty from very easy to very difficult. Lower scores indicate greater activity and social participation limitations. |
Baseline to 12 weeks
|
|
Stage A: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
Time Frame: Baseline to 12 weeks
|
Change from Stage A baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Baseline to 12 weeks
|
|
Stage A: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
Time Frame: Baseline to 12 weeks
|
Change from Stage A baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Baseline to 12 weeks
|
|
Stage B: Time to First Adjusted INCAT Disability Scale Score Deterioration Relative to Baseline
Time Frame: Up to 52 weeks
|
Time to first adjusted INCAT disability scale score deterioration relative to Stage B baseline will be reported. |
Up to 52 weeks
|
|
Stage B: Time to First Switch to Intravenous Immunoglobulin (IVIg) or Other Standard of Care (SoC) as a Result of Investigator-assessed Lack of Efficacy as Confirmed by an Independent RAC Relative to Baseline
Time Frame: Up to 52 weeks
|
Time to first switch to IVIg or other SoC as a result of investigator-assessed lack of efficacy as confirmed by an independent Relapse Adjudication Committee (RAC) relative to Stage B baseline will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in Adjusted INCAT Disability Score
Time Frame: Up to 52 weeks
|
Change from Stage B baseline over time in adjusted INCAT disability score will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in MRC Muscle Grading Scale Sum Score
Time Frame: Up to 52 weeks
|
Change from Stage B baseline over time in MRC Muscle Grading Scale Sum score will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in I-RODS Centile Score
Time Frame: Up to 52 weeks
|
Change from Stage B baseline over time in I-RODS centile score will be reported. |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
Time Frame: Up to 52 weeks
|
Change from Stage B baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Up to 52 weeks
|
|
Stage B: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
Time Frame: Up to 52 weeks
|
Change from Stage B baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer). |
Up to 52 weeks
|
|
Stage B: Number of Participants with Binary Response Endpoint Satisfying all 4 Conditions: a) An Improved Adjusted INCAT Disability Score Compared to Baseline; b) Not Relapsing; c) Not Switching to SoC; d) Not Discontinuing Treatment
Time Frame: Up to 52 weeks
|
Number of participants with Binary response endpoint satisfying all 4 conditions: a) an improved adjusted INCAT Disability Score compared to Stage B baseline; b) not relapsing; c) not switching to SoC; d) not discontinuing treatment, will be reported. |
Up to 52 weeks
|
|
Percentage of Participants with Treatment-emergent Adverse Events (TEAEs)
Time Frame: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Percentage of Participants with Serious Adverse Events (SAEs)
Time Frame: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
SAE is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Change in Electrocardiogram (ECG) Values Over Time
Time Frame: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with change in ECG values over time will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Change in Vital Signs Values Over Time
Time Frame: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with change in vital signs values over time will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Change in Clinical Laboratory Values Over Time
Time Frame: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with change in clinical laboratory values over time will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Clinically Significant ECG Abnormalities
Time Frame: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with clinically significant ECG abnormalities will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Clinically Significant Vital Signs Abnormalities
Time Frame: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with clinically significant vital signs abnormalities will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Clinically Significant Clinical Laboratory Abnormalities
Time Frame: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with clinically significant clinical laboratory abnormalities will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Percentage of Participants with Suicidal Ideation or Suicidal Behavior based on the Columbia-Suicide Severity Rating Scale (C-SSRS)
Time Frame: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Percentage of participants with suicidal ideation or suicidal behavior based on the C-SSRS will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Serum Nipocalimab Concentrations Over Time in Participants Receiving Active Study Intervention
Time Frame: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Serum nipocalimab concentrations over time in participants receiving active study intervention will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Anti-drug Antibodies (ADA) to Nipocalimab
Time Frame: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with ADA to Nipocalimab will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Titers of ADA to Nipocalimab
Time Frame: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Titers of ADA to nipocalimab will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Number of Participants with Neutralizing Antibodies (NAb) to Nipocalimab
Time Frame: Stage A: 12 weeks; Stage B: Up to 52 weeks
|
Number of participants with NAb to Nipocalimab will be reported. |
Stage A: 12 weeks; Stage B: Up to 52 weeks
|
|
Change from Baseline in Total Serum Immunoglobulin (IgG) Concentrations Levels Over Time
Time Frame: Stage A: Baseline to 12 weeks; Stage B: Baseline up to 52 weeks
|
Change from baseline in total serum IgG concentrations levels over time will be reported. |
Stage A: Baseline to 12 weeks; Stage B: Baseline up to 52 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Pathologic Processes
- Neuromuscular Diseases
- Chronic Disease
- Disease Attributes
- Autoimmune Diseases
- Immune System Diseases
- Peripheral Nervous System Diseases
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Polyneuropathies
- Polyradiculoneuropathy
- Pathological Conditions, Signs and Symptoms
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Other Study ID Numbers
Other Study ID Numbers
- CR109195
- 80202135CDP3001 (Other Identifier: Janssen Research & Development, LLC)
- 2021-003234-37 (EudraCT Number)
- 2023-508425-28-00 (Registry Identifier: EUCT number)
- 2023 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.